Vaxcyte Inc
PCVXHealthcare|Biotechnology|USA
$58.20
-1.62 (-2.71%)
Tangible Book
$20.76
Earnings Power
$7.32
Clinical Trials (9)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07365826 A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age | Pneumococcal Vaccines | P3 | Active | 1,390 | RCT, Double-blind | 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok), Placebo |
| NCT07284654 Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49 | Pneumococcal Vaccines | P3 | Active | 4,049 | RCT, Double-blind | 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 |
| NCT07425392 Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination | Pneumococcal Vaccines | P3 | Active | 752 | RCT, Double-blind | 31-valent pneumococcal conjugate vaccine, PCV20 |
| NCT06720038 A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants | Pneumococcal Vaccines | P2 | Active | 900 | RCT, Double-blind | 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-31, 0.5 mL dose of PCV20, 0.5 mL of the High-PFS dose VAX-31 |
| NCT07616934 A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-A1 in Healthy Young Adults | Group A Streptococcal Infection | P1 | Recruiting | 80 | RCT, Double-blind | Placebo, VAX-A1 Low, VAX-A1 Mid, VAX-A1 High |
| NCT05844423 Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants | Pneumococcal Vaccines | P2 | Completed | 802 | RCT, Double-blind | 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24 |
| NCT05297578 Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults | Pneumococcal Vaccines | P2 | Completed | 207 | RCT, Double-blind | 24-Valent Pneumococcal Conjugate Vaccine, Pneumococcal 20-valent Conjugate Vaccine |
| NCT06151288 Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults | Pneumococcal Vaccines | P1P2 | Completed | 1,015 | RCT, Double-blind | 31 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine |
| NCT05266456 Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults | Pneumococcal Vaccines | P1P2 | Completed | 835 | RCT, Double-blind | 24 valent pneumococcal conjugate vaccine, 20 valent pneumococcal conjugate vaccine |